Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
about
Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease.Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.Clinical impact of immunomonitoring in the treatment of inflammatory bowel disease.Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives.TNF blocking therapies and immunomonitoring in patients with inflammatory bowel diseasePharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease.Use of anti-TNF drug levels to optimise patient management.Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis.Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.A Personalized Approach to Managing Inflammatory Bowel Disease.Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-α antibodies in ulcerative colitis.A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays.Development of a universal anti-adalimumab antibody standard for interlaboratory harmonization.Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease.Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.Interleukin(IL)-36α and IL-36γ Induce Proinflammatory Mediators from Human Colonic Subepithelial Myofibroblasts.Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease.Immunogenicity of biologics in inflammatory bowel disease.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Response to Bodini et al.A case of Crohn's disease that developed anti-infliximab and anti-adalimumab antibodies.Surface plasmon resonance-based methodology for anti-adalimumab antibody identification and kinetic characterization.Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease.Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study.Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease.“Blindly” ADA Dose Escalation to 80 mg Weekly in Crohnʼs Disease Patients with LORAdalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease
P2860
Q33874790-474AAAEC-823B-4564-982D-177CE155B74CQ36089928-D689DF06-A7C9-4445-9565-C2C339477CB3Q37624487-4824B8A3-F662-4173-B8F8-DC3252FD2EC2Q38193349-AD7C57CA-7521-48CA-AD93-1EB634EC2519Q38206507-3EF19D13-5BF9-4FEC-8641-70783AC2FBE6Q38211991-1ED2B0FE-04F0-4A03-8339-E04862FFB00AQ38365049-550748FE-C2AE-4089-BBE9-5BEB9B4221B2Q38608951-835761F5-9B39-4B07-8F4A-05124CB0AAF6Q38633561-EF086103-BBB3-4151-878F-3D4746D84EB6Q38695300-B6C38B26-50E3-4D73-B6BB-14DBBB441E0FQ38798678-076AC5DA-32FA-48CB-B625-137B2240F44AQ38822920-A488B6E2-9CFF-4A52-A882-5F0592E9CE8FQ38833619-06DA50F9-4F2D-4F90-9328-27E3FAFCF3B9Q38906748-76E5014E-7693-4471-9A56-265A48F9F23EQ38923616-8AE4A2E0-96A1-4420-A2C8-9AB7E4F1A52AQ38987484-4552B022-56AA-4F40-B905-52BD53DF40D9Q39030608-55A2627D-2812-41F8-9E2E-18322D56610BQ39371316-128DBF88-42EC-48C9-A381-DCAC03700003Q42077731-3F8C48B8-7F19-4A02-9E42-C0DC165701BAQ43510384-1DCB1111-8F91-40FC-966A-CA054B91C120Q43988900-45C76CA0-40A7-4B93-B757-518F7F774BB8Q45200648-4022E6BD-7FFF-4CD7-A461-D9286F353DCCQ47805665-CC101D4F-CB16-4FBD-A900-97341C2E3D90Q48535499-EECC2D38-73A3-416E-A3D8-0654DB10A7D9Q49404676-8FFAC442-D7A0-4F66-B545-75B53D7FD7D3Q50065301-306B5BB9-B833-4FC0-998A-30A63BC4F810Q50951827-47D1670E-5323-472D-A6A7-495F61AE0959Q51041658-29CC53FD-DBF2-49BE-A031-11B87275FD33Q51486721-FBD57908-7FB7-4B4B-BA57-59B0EC9499D7Q51647910-46B0B4C0-6EB3-47CB-970A-D7F230E9F0E2Q53813065-4EC73B5E-07FE-4928-A4C0-165060E599C8Q55223956-FC95CFEA-B1E6-4610-8807-5BE4D437F367Q55432449-44495D6D-96D4-418E-9AA7-395B333745CFQ58811079-4F3E2981-8113-4031-A28A-8F492747144AQ59120251-FD874D8C-B981-4969-9B3F-E540A55610DA
P2860
Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Clinical utility of newly deve ...... patients with Crohn's disease.
@en
Clinical utility of newly deve ...... patients with Crohn's disease.
@nl
type
label
Clinical utility of newly deve ...... patients with Crohn's disease.
@en
Clinical utility of newly deve ...... patients with Crohn's disease.
@nl
prefLabel
Clinical utility of newly deve ...... patients with Crohn's disease.
@en
Clinical utility of newly deve ...... patients with Crohn's disease.
@nl
P2093
P2860
P1476
Clinical utility of newly deve ...... patients with Crohn's disease
@en
P2093
Akira Andoh
Kenichiro Takahashi
Masaya Sasaki
Shigeki Bamba
Takehide Fujimoto
Tomoyuki Tsujikawa
Yoshihide Fujiyama
P2860
P304
P356
10.1007/S00535-013-0803-4
P577
2013-04-11T00:00:00Z